Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets): A Pragmatic, Multi-Center, Randomized Controlled Trial
退伍军人透析第一年增量血液透析 (IncHVets):一项务实、多中心、随机对照试验
基本信息
- 批准号:10486289
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-10-01 至 2027-09-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAmericanAncillary StudyBlood VesselsCachexiaCardiacCardiovascular systemCaregiver BurdenCaringClient satisfactionClinicClinic VisitsClinicalClinical TrialsCosts and BenefitsDialysis patientsDialysis procedureDoseEatingEligibility DeterminationEmergency department visitEnd stage renal failureEventFatigueFrequenciesFutureGDF15 geneGrowthHealthcare SystemsHemodialysisHospitalizationHuman ResourcesHypotensionHypotensivesImpaired healthInflammationInflammatoryInjury to KidneyInterventionKidneyKidney DiseasesLeftLeft Ventricular MassLifeLongevityMaintenanceMalnutritionMeasuresMedical centerMuscleNutritionalNutritional statusOrganOutcomeOutcome MeasureOutpatientsOutputParentsPatient Outcomes AssessmentsPatientsPhysical FunctionPhysical PerformancePopulationPragmatic clinical trialProteinsProtocols documentationProviderRandomized, Controlled TrialsRegimenRenal functionResearch DesignResearch PersonnelResidual stateResourcesSafetyScheduleSerumSiteSymptomsSystemTestingTimeTime trendUreaUrineVeteransVeterans Health AdministrationWithdrawalarmcopingcostdesignexperiencefrailtyfunctional statushealth care service utilizationhealth related quality of lifehyperkalemiaimprovedindexingmortalitymortality riskmuscle formnutritionphysical conditioningpragmatic studyprecision medicinepreferencepreservationprimary endpointprimary outcomesafety assessmentsafety outcomessafety testingscale upsecondary endpointsecondary outcomestandard of caresurvival predictionwasting
项目摘要
PROJECT SUMMARY
Each year approximately 12,000 Veterans develop end-stage renal disease (ESRD) and initiate dialysis
treatment. These patients comprise >10% of the US incident ESRD population. Dialysis is costly and
associated with impaired health-related quality of life (HRQOL) and high mortality risk, particularly in the first
dialysis year. The current paradigm is to start treatment with full-dose thrice-weekly hemodialysis (HD)
irrespective of patients' residual kidney function (RKF), and this abrupt transition increases patients' and care-
partners' burden and suffering and may limit their preferences. Furthermore, recent evidence suggests that
Veterans who receive dialysis in a VA center have greater survival compared to those treated in non-VA units.
Although not currently the standard of care, evidence suggests that a gradual or incremental dialysis
transition using an initial twice-weekly HD schedule may confer substantial benefits including more dialysis-
free time, longer RKF preservation, vascular access longevity, less intradialytic hypotension and end-organ
damage, reduced post-dialysis fatigue, and less patient suffering. Hence, an incremental dialysis transition
may result in improved HRQOL through improved physical function, less fatigue, greater energy, and
improved patient satisfaction and life participation by mitigating the burden of excessive dialysis in daily life.
Pragmatic studies with immediate clinical impact are urgently needed to shift the focus of dialysis from an
abrupt thrice-weekly HD start to a safe and effective personalized dialysis regimen. Moreover, implementing a
twice-weekly HD schedule would allow 20% more Veterans to receive care within a VA-based dialysis unit.
In the spirit of RFA CX-21-006 for clinical trials, in this multiple-PI, multi-site, pragmatic, 1:1 randomized
controlled trial (RCT), parallel with Veterans' routine dialysis therapy, we will test the safety and efficacy of an
incremental twice-weekly HD protocol, compared to standard-of-care thrice-weekly HD, in Veterans who meet
predefined eligibility criteria. We plan to compare twice-weekly (incremental) with thrice-weekly (conventional)
HD initiation in 252 Veterans with incident ESRD, who will transition to maintenance HD therapy in six VA
centers. Using quarterly assessments for up to 12 months, we will examine the Short Form 36 (SF36) HRQOL
physical component score as the primary outcome, as well as Dialysis Symptom Index and SF36 energy/
fatigue score as secondary endpoints. Additional secondary outcomes will include preservation of RKF,
dialysis adequacy, nutritional status, and protein-energy wasting markers to be measured quarterly. Safety
assessments will include mortality, dialysis withdrawals, emergency room visits, hospitalizations,
hyperkalemia, and major adverse cardiovascular events. In a substudy examining exploratory outcomes in
112 Veterans from three VA centers in the parent trial, we will also examine of cardiac measures including left
ventricular mass, as well as nutritional/physical function indices of muscle mass and physical performance.
Our proposed pragmatic RCT addresses a major unmet need in Veterans with incident ESRD initiating
dialysis by focusing on improving HRQOL and preserving RKF, the two strongest predictors of survival and
patient satisfaction. The results of this study may enable more Veterans to receive therapy in a VA based
dialysis center. Our study may lead to a paradigm shift with immediate impact on kidney care in Veterans and
in the broader ESRD population. The pragmatic design will permit a rapid scaling-up of the interventions in
larger settings since the RCT takes advantage of resources and personnel that are readily available in VA
centers under experienced investigators and clinicians across multiple VA sites nationwide. This proposed
study challenges the current standard of care of outright thrice weekly HD in the first year of dialysis therapy,
during which patients' suffering and mortality are the highest, and is less likely to be supported by for-profit
dialysis providers given the perceived reduction in revenue if twice-weekly HD is to be implemented broadly.
项目摘要
每年约有12,000名退伍军人发展为终末期肾病(ESRD)并开始透析
治疗这些患者占美国事件ESRD人群的>10%。透析费用昂贵,
与健康相关的生活质量(HRQOL)受损和高死亡风险相关,特别是在第一次
透析年份目前的模式是开始治疗与全剂量每周三次血液透析(HD)
无论患者的残余肾功能(RKF)如何,这种突然的转变都会增加患者的负担和护理-
这可能会减少伴侣的负担和痛苦,并可能限制他们的偏好。此外,最近的证据表明,
与在非退伍军人管理局单位接受透析的退伍军人相比,在退伍军人管理局中心接受透析的退伍军人的生存率更高。
虽然目前不是标准治疗,但有证据表明,渐进或增量透析
使用最初的每周两次HD时间表的过渡可能会带来实质性的益处,包括更多的透析-
空闲时间、更长的RKF保存时间、血管通路寿命、更少的透析中低血压和终末器官
损伤,减少透析后疲劳,减少患者痛苦。因此,增量透析过渡
可能通过改善身体功能、减少疲劳、增加能量,
通过减轻日常生活中过度透析的负担,提高患者满意度和生活参与度。
迫切需要具有直接临床影响的实用研究,以将透析的重点从
突然开始每周三次HD,以获得安全有效的个性化透析方案。此外,实施A
每周两次的HD计划将使20%以上的退伍军人在VA透析单位接受护理。
本着RFA CX-21-006临床试验的精神,在此多PI、多中心、务实、1:1随机化
对照试验(RCT),与退伍军人的常规透析治疗平行,我们将测试一种治疗的安全性和有效性。
在满足以下条件的退伍军人中,与标准治疗每周三次HD相比,每周两次递增HD方案
预定义的资格标准。我们计划比较每周两次(增量)和每周三次(常规)
252例发生ESRD的退伍军人开始HD治疗,他们将在6例VA中过渡到维持HD治疗
中心.使用长达12个月的季度评估,我们将检查简表36(SF 36)HRQOL
身体成分评分作为主要结局,以及透析症状指数和SF 36能量/
疲劳评分作为次要终点。其他次要结局将包括保留RKF,
透析充分性、营养状况和蛋白质-能量消耗标记物,每季度测量一次。安全
评估将包括死亡率,透析退出,急诊室就诊,住院,
高钾血症和主要不良心血管事件。在一项研究探索性结局的子研究中,
在母试验中,来自三个VA中心的112名退伍军人,我们还将检查心脏指标,包括左心室功能。
心室质量,以及肌肉质量和体能的营养/身体功能指数。
我们提出的务实RCT解决了退伍军人事件ESRD启动的一个主要未满足的需求
透析的重点是改善HRQOL和保留RKF,这是生存率的两个最强预测因子,
患者满意度。这项研究的结果可能使更多的退伍军人接受治疗,在一个VA为基础的
透析中心我们的研究可能会导致一个范式的转变,对退伍军人的肾脏护理产生直接影响,
在更广泛的ESRD人群中。务实的设计将允许迅速扩大干预措施,
由于RCT利用了VA中随时可用的资源和人员,因此设置更大
在全国多个VA中心,由经验丰富的研究者和临床医生管理。这一拟议
研究挑战了透析治疗第一年每周三次HD的现行标准治疗,
在此期间,患者的痛苦和死亡率是最高的,并且不太可能得到营利性组织的支持。
考虑到如果广泛实施每周两次HD,透析提供商的收入将减少。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kamyar Kalantar-Zadeh其他文献
Kamyar Kalantar-Zadeh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kamyar Kalantar-Zadeh', 18)}}的其他基金
Plant-Focused Nutrition in Patients with Diabetes and Chronic Kidney Disease (PLAFOND Study): A Pilot/Feasibility Study
糖尿病和慢性肾病患者的植物性营养(PLAFOND 研究):试点/可行性研究
- 批准号:
10586677 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial (CONDOR TRIAL)
透析患者连续血糖监测克服血糖异常试验(CONDOR TRIAL)
- 批准号:
10587470 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Defining Optimal Transitions of Care in Advanced Kidney Disease: Conservative Management vs. Dialysis Approaches
定义晚期肾病护理的最佳转变:保守治疗与透析方法
- 批准号:
10436989 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Defining Optimal Transitions of Care in Advanced Kidney Disease: Conservative Management vs. Dialysis Approaches
定义晚期肾病护理的最佳转变:保守治疗与透析方法
- 批准号:
10264944 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Racial and Cardiovascular Risk Factor Anomalies in CKD
CKD 中的种族和心血管危险因素异常
- 批准号:
8635349 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Comparative Effectiveness of Home Hemodialysis versus Kidney Transplantation in t
家庭血液透析与肾移植在治疗中的效果比较
- 批准号:
8741928 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Racial and Cardiovascular Risk Factor Anomalies in CKD
CKD 中的种族和心血管危险因素异常
- 批准号:
8532600 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Racial and Cardiovascular Risk Factor Anomalies in CKD
CKD 中的种族和心血管危险因素异常
- 批准号:
8811934 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Comparative Effectiveness of Home Hemodialysis versus Kidney Transplantation in t
家庭血液透析与肾移植在治疗中的效果比较
- 批准号:
8652787 - 财政年份:2013
- 资助金额:
-- - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
-- - 项目类别: